



60° Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Washington DC, April 29, 2015 - **60° Pharmaceuticals**, a company **focused on development of therapeutics for tropical diseases**, announced today it has been selected to present at the Cavendish Global Health Impact Forum May 10th to May 14th in La Jolla, California.

The Forum is intended to help family offices and foundations develop and implement their pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. The Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.

A unique gathering of leading family offices, Cavendish Impact Forums are hosted three times a year by leading institutions around the world. This Forum is being co-hosted by the community of La Jolla, including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, "The theme of our La Jolla, California Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.' With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies to identify organizations that meet the required standard of excellence.

"The quality and originality of **60° Pharmaceutical's** research and scientific insights in **tropical diseases research** positions them to make a major contribution to the prevention and treatment of **malaria and dengue**," Cavendish said.

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approaches to **prevent and treat tropical diseases** afflicting populations around the world today," said **Dr. Geoffrey Dow, 60° Pharmaceuticals CEO**. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over \$190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation

- more -

and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

About 60° Pharmaceuticals

60° Pharmaceuticals is a privately-held company founded in 2010 with a mission to develop small molecule therapeutics for tropical diseases. We are focused on development of products with dual use application in the travel medicine market and tropical countries. Our development portfolio includes three repositioned dengue therapeutics and an antimalarial drug that has completed Phase III trials. In 2015 we plan to initiate a Phase II study in dengue patients in Singapore in collaboration with prominent Singaporean research institutions.

60° Pharmaceuticals, after executing an exclusive licensing deal and research agreement with the United States Army in 2014, is preparing for the commercial launch of tafenoquine for traveler's malaria prophylaxis. Due to its unique mode of action, tafenoquine also has potential utility for community prophylaxis in malaria endemic countries in combination with existing control measures. Our mission is supported through substantial in kind funding from the United States Department of Defense and other agencies of the U.S. government. 60° Pharmaceuticals is headquartered in Washington DC, with a subsidiary in Australia.

Further information is available on the Company's website, <http://www.60degreespharma.com>

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

For more information: <http://cavendishglobal.com>

For further information contact:

Roseann Rosetta,
Director, Account Management
Integrated Marketing Services
rrosetta@imsworld.com
609-683-9055 x247

Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com
Tel: +1-917-576-1435